Polyhexanide
Pharmaceutical compound
Polyhexanide (polyhexamethylene biguanide, PHMB) is a polymer used as a disinfectant and antiseptic. In dermatological use, it is spelled polihexanide (INN) and sold under various brand names. PHMB has been shown to be effective against Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Candida albicans, Aspergillus brasiliensis, enterococci, and Klebsiella pneumoniae. Polihexanide, sold under the brand name Akantior is a medication used for the treatment of Acanthamoeba keratitis.
Products containing PHMB are used for inter-operative irrigation, pre- and post-surgery skin and mucous membrane disinfection, post-operative dressings, surgical and non-surgical wound dressings, surgical bath/hydrotherapy, chronic wounds like diabetic foot ulcer and burn wound management, routine antisepsis during minor incisions, catheterization, first aid, surface disinfection, and linen disinfection. PHMB eye drops have been used as a treatment for eyes affected by Acanthamoeba keratitis. Ready-to-use preparations for direct application in or on the human body in clinical use: Lavanid, Lavasept, Prontoderm, Prontomed, Prontosan, Serasept, Suprasorb X+PHMB und Suprasorb P+PHMB
It is sold as a swimming pool and spa disinfectant in place of chlorine or bromine based products under the name Baquacil.
PHMB is also used as an ingredient in some contact lens cleaning products, cosmetics, personal deodorants and some veterinary products. It is also used to treat clothing (Purista), purportedly to prevent the development of unpleasant odors.
The PHMB hydrochloride salt (solution) is used in the majority of formulations.
01Use in Acanthamoeba keratitis treatment
Polihexanide is indicated for the treatment of Acanthamoeba keratitis in people aged 12 years of age and older.
Legal status
In May 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Akantior, intended for the treatment of Acanthamoeba keratitis, a severe, progressive and sight threatening corneal infection characterized by intense pain and photophobia. Acanthamoeba keratitis is a rare disease primarily affecting contact lens wearers. The applicant for this medicinal product is SIFI SPA. Polihexanide was approved for medical use in the European Union in August 2024.
02Safety
In 2011, polyhexamethylene biguanide was classified as category 2 carcinogen by the European Chemical Agency, but it is still allowed in cosmetics in small quantities if exposure by inhalation is impossible.
03Name controversy
In some sources, particularly when listed as a cosmetics ingredient (INCI), the polymer is wrongly named as polyaminopropyl biguanide.
Sources and credits
This article is adapted from the Wikipedia article “Polyhexanide”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- Polyhexanide.svg by Ilgom (talk), Public domain
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.